Loren Pickart suggests total treatment doses of 100-200mg administered over 30-60 days, or approximately 1.1 mg/kg body weight
doi:10.1093/ajhp/zxae105
Salerno about her persistent fatigue, chronic migraines, and unrelenting joint pain
The lipid-lowering effects of GLP-1 medications appear to be mediated through several mechanisms: Weight loss : Reduction in body weight and visceral adiposity improves insulin sensitivity and hepatic lipid metabolism Improved glycemic control : Better glucose regulation reduces hepatic very-low-density lipoprotein (VLDL) production Potential hepatic effects : Some evidence suggests GLP-1 signaling may influence lipid metabolism, though human data are limited Reduced postprandial lipemia : Delayed gastric emptying decreases triglyceride excursions after meals It is important to note that GLP-1 receptor agonists should not be considered primary lipid-lowering agents
For patients who have had a cardiovascular event and heart failure, SGLT2 inhibitors are recommended as first-line treatment, GLP-1 RAs or metformin as second-line treatment, and DPP4 inhibitors, acarbose, or insulin as third-line treatment [5]
This pro-osteogenic effect operates through the cAMP/CREB signaling pathway
